SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabet is seeing volatile price action as investors weigh an impressive revenue and earnings beatdriven by explosive 82% growth in Google Cloudagainst concerns over massive capital expenditure increases. While the community is debating whether these aggressive AI infrastructure investments are a necessary engine for long-term dominance or a drag on near-term margins, bulls are pointing to the record-breaking usage of Gemini and a massive contracted backlog as proof of sustainable demand.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is facing significant downward pressure as investors react to a disappointing earnings report, highlighted by compressed margins and negative free cash flow driven by aggressive AI and robotics spending. While the community remains deeply polarized, discussions are heavily focused on the viability of future product timelines like the Robotaxi and Optimus, with some traders debating potential M&A scenarios with SpaceX while others warn of further valuation corrections.

Space Exploration Technologies Corp. (SpaceX) designs, manufactures, and launches advanced rockets and spacecraft, including the fully reusable Starship and Super Heavy rocket system, targeting missions to Earth orbit, the Moon, Mars, and beyond. The company is based in Hawthorne, CA and has subsidiaries in Luxembourg and the United States. The company operates Starlink, a low-Earth orbit satellite constellation that delivers high-speed broadband internet worldwide. SpaceX is dedicated to advancing space technology with the goal of enabling human life on other planets. The company was founded in 2002 by Elon Reeve Musk, Kimbal Musk, Michael Kives. Elon Reeve Musk has been the CEO since 2002.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX is currently trending due to intense volatility and significant downward pressure as investors grow increasingly concerned about the massive upcoming share unlock event in August. The community remains deeply divided, with bulls viewing the current price as an historic buying opportunity ahead of key launch and earnings catalysts, while bears warn of a looming supply flood that could drive the stock to significantly lower levels.

Alphabet Inc - Ordinary Shares - Class C

Alphabet is trending as investors scrutinize its surging capital expenditures directed at AI infrastructure, even as the company delivered a significant earnings and cloud revenue beat. Market conversation is currently polarized between bulls who view the heavy spending as a necessary foundation for long-term growth and bears concerned about potential margin compression and the sustainability of record AI-driven backlogs.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

United States Oil Fund (USO) is trending as traders debate the impact of escalating Middle East tensions, specifically recent Houthi maritime threats and potential Strait of Hormuz disruptions, against ongoing speculation regarding diplomatic ceasefires. Community sentiment is deeply divided, with many market participants actively discussing the risk of supply-driven price spikes versus the possibility of a tactical reversal driven by geopolitical deal-making.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow is driving intense market conversation following a solid double-beat earnings report that highlighted strong AI monetization, with its AI annual contract value recently crossing the $1 billion milestone. The community is actively debating whether ServiceNow is successfully positioning itself as an essential enterprise 'AI control tower' despite broader software sector volatility and concerns regarding valuation and margin pressures.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is experiencing significant downward pressure and a 52-week low as investors grow frustrated with the lack of commercial revenue and the pace of the company's manufacturing roadmap ahead of its earnings report. While the community remains deeply divided between long-term bulls highlighting new partnerships and the technological potential of ceramic separators, and bearish voices focusing on insider selling and the long lead time to mass production, market participants are bracing for volatility around the upcoming financial update.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as the community prepares for a critical July 29 FDA advisory committee meeting and a subsequent PDUFA date in August, with investors closely monitoring regulatory label negotiations and potential patent litigation. Supporters are emphasizing the strength of the HOPE-3 clinical trial data and the company's recent expansion into a major new facility as key catalysts for potential long-term value, despite ongoing volatility driven by intense short-selling activity and skepticism regarding patent claims.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is currently trending as investors focus on the company's upcoming earnings report, with community discussion centered on potential foundry partnerships, cost-cutting initiatives, and speculation about its strategic role in the evolving AI infrastructure market. While some participants are wary of broader macroeconomic pressures and historical earnings volatility, others are looking for signs of a turnaround fueled by institutional accumulation and key enterprise collaborations.

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Arrowhead Pharmaceuticals Inc.

Arrowhead Pharmaceuticals is trending due to the robust Phase 3 data for plozasiran in treating severe hypertriglyceridemia, which demonstrated significant reductions in triglycerides and acute pancreatitis risks. The community is actively discussing these positive results as a fundamental re-rate for the company, while simultaneously debating its potential for future acquisition and the broader, multi-indication promise of their RNAi delivery platform.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer

Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer PR Newswire LONDON, July 22, 2026 Approval based on ARROS-1 phase I/II trial...

Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for

Biogen (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GSK (GSK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GSK Discontinues Development of Camlipixant for Refractory Chronic Cough

GSK drops camlipixant's refractory chronic cough program after mixed phase III results, but the drug remains in a phase IIb study for irritable bowel syndrome.

GSK's Jemperli Delivers Promising Interim Data in Rectal Cancer

GSK reports positive interim phase II AZUR-1 data as Jemperli meets the primary endpoint in rectal cancer, supporting potential regulatory filings.

Nuvalent Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nuvalent, Inc. - NUVL

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Nuvalent, Inc. (NasdaqGS: NUVL) to GSK plc (NYSE: GSK). Under the terms of the proposed transaction, shareholders of Nuvalent will receive $124.00...

GSK's Jemperli May Help Some Rectal Cancer Patients Avoid Surgery

GSK Jemperli shows sustained complete responses in dMMR/MSI-H rectal cancer, potentially eliminating the need for surgery or chemo.read more...

GSK Adds Positive Phase 3 Lung Cancer Data, Ends Alector Partnership

GSK-backed Ris-Rez posts positive Phase 3 survival data in small-cell lung cancer as the company moves to end its collaboration with Alector.read more...

GSK plc (GSK) Launches Tender Offer to Acquire Nuvalent Inc. for $124 Per Share

GSK plc (GSK) Launches Tender Offer to Acquire Nuvalent Inc. for $124 Per Share...

FDA Expands IONS' Tryngolza Label to Treat Severe Hypertriglyceridemia

Ionis wins FDA approval to expand Tryngolza to severe hypertriglyceridemia, opening a broader market as the first approved treatment for the condition. 

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

GSK Plc - ADR

NUVL Stock Surges 39% Premarket – Why Is GSK Buying This Boston-Based Oncology Company?

Equity

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	$1.24	--	--	N/A
Q1 '26	$1.15	$1.26	8.75%	BEAT
Q4 '25	$0.64	$0.70	8.50%	BEAT
Q3 '25	$1.26	$1.46	15.86%	BEAT
Q2 '25	$1.17	$1.24	5.58%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

GSKGlaxosmithkline plc - ADR

Upcoming Earnings: Q2 '26

Historical Earnings

Latest GSK News